SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
MDXH

MDxHealth SA (NASDAQ:MDXH)

BE · Delayed Price · Currency is USD
Also listed: 0O8G.L, MDXH.BRHealthcare · Medical - Diagnostics & Research
$0.11-$0.01 (-8.52%)
 
Market cap
$10.2M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 4, 2021
Market Cap$10.25M-96.8%
Revenue (ttm)$72.63M-18.1%
Net Income-$40.16M+11.0%
EPS-$0.68+51.5%
Shares Out95.42M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,033,296
Open$0.12
Previous Close$0.12
Day's Range$0.10 - $0.12
52-Week Range$0.10 - $4.34
Beta0.39
AnalystsBuy
Price Target$2.50(+2227.75%)
Earnings Daten/a
-6.30% (1D)
No price history available.

About MDXH

MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.

Address
CAP Business Center, Herstal, WA, 4040, BE
Market Cap
10 million
Employees
364
Industrial Classification
Medical - Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$1.00M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Hold
0 Buy1 Hold0 Sell

1 firm rating MDXH in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From MDXH’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars
1 Day
-8.52%
5 Days
-23.29%
1 Month
-50.00%
6 Months
-87.00%
1 Year
-96.77%

$MDXH stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in MDXH holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MDXH's directors and management

Net Shares Purchased by Insiders−3M−1.5M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MDXH Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New MDXH patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MDXH from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in MDXH

IWCiShares Micro-Cap ETF$14.95K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from MDXH’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
24.54
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
35

News check: Q3 2026 results show revenue miss and net loss, though commercial reset narrative suggests management positioning for 2027 recovery.

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$1.00M
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.